Clinical trials: Neoplasm of Breast
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Recurrent Breast Cancer, Stage IV Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase II trial to study the effectiveness of combination chemotherapy with or without trastuzumab in treating women who have metastatic breast cancer.
- Trial name
- NCT00004888
- Testing
- pegylated liposomal doxorubicin hydrochloride, docetaxel, trastuzumab
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Radiologic Evaluation and Breast Density (READ)
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
- Trial name
- NCT00117663
- Testing
- temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months
- Where
- United States
- Volunteers
- 1,704 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Cancer
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
Some tumors use estrogen in the body to assist with growth. Letrozole is a drug that is prevents cells from producing estrogens. This should assist with the slowing of growth of tumor cells.
- Trial name
- NCT02010021
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
The primary hypothesis to be tested is: The detection of breast cancer will be increased with tomosynthesis (3D) imaging
- Trial name
- NCT01669148
- Testing
- Tomosynthesis, Conventional
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Malignant Neoplasm of Breast Stage IV
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
This retrospective observational study is designed to assess the response to treatment with fulvestrant at a dose of 500 mg/month with a loading dose of 500 mg (LD-500), in terms of progression free survival (PFS), overall…
- Trial name
- EFFICACY (NCT01509625)
- Testing
- Fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 272 people
- Sponsor
- Isabel Blancas
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist.
- Trial name
- NCT01823835
- Testing
- GDC-0810, LHRH Agonist, Palbociclib
- Where
- 14 sites in United States, Netherlands and 2 more
- Volunteers
- 152 people
- Sponsor
- Genentech, Inc.
Cancer, Breast, Inflammation
Hypofractionated Radiotherapy in Breast Cancer
As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation…
- Trial name
- NCT03167359
- Testing
- Hypofractionated Simultaneous Integrated Boost Radiotherapy
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Emory University
Breast Cancer
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to…
- Trial name
- NCT03783546
- Testing
- Acupuncture, Usual Care
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast…
- Trial name
- NCT01525589
- Testing
- PM01183
- Where
- 9 sites in United States, Spain
- Volunteers
- 111 people
- Sponsor
- PharmaMar
Breast Cancer
Decision Support Workshop for Breast Reconstruction
The purpose of this study is to determine the effectiveness of a pre-consultation decision support workshop for breast reconstruction after breast cancer, in facilitating the decision-making process, compared to routine…
- Trial name
- DSW (NCT01857882)
- Testing
- Decision Support Workshop
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)
The purpose of this investigation, using hardcopy film, is to compare the accuracy of the Philips MammoDiagnost DR (FFDM device) and screen-film (SF) mammography in detection of breast cancer among women undergoing screening or…
- Trial name
- NCT00999596
- Where
- 3 sites in United States, Germany
- Volunteers
- 107 people
- Sponsor
- Philips Healthcare
Breast Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline…
- Trial name
- NCT00373113
- Testing
- Capecitabine, Sunitinib malate
- Where
- 123 sites in Argentina, Australia and 21 more
- Volunteers
- 482 people
- Sponsor
- Pfizer
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Metastatic Breast Cancer
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line…
- Trial name
- CLEOPATRA (NCT00567190)
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 322 sites in United States, Argentina and 24 more
- Volunteers
- 808 people
- Sponsor
- Genentech, Inc.
Early Breast Cancer
Arthralgia During Anastrozole Therapy for Breast Cancer
The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.
- Trial name
- NCT00323479
- Testing
- Anastrozole
- Where
- 5 sites in France
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.